The Bridge program does not include two other classes of weight management medication combinations that were available before GLP-1s came on the market, and are available at lower cost in generic form
While adequately powered for the primary outcome, 1415 patients per group is relatively small
vigorous shaking must be avoided to prevent peptide denaturation
Peak severity: Months 4 to 8
Reasonable expectations (what success typically looks like clinically) Success is: Better appetite control without daily misery Steady fat loss while maintaining strength and function Improved lab and metabolic trends when relevant A plan you can live with after the active loss phase ends If the only metric is rapid scale loss, patients often pay for it laterwith regain, fatigue, hair shedding, constipation, or loss of lean mass
Retatrutide should not be used during pregnancy or breastfeeding, as no human safety data exist for these situations